The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $12.07 in the prior trading day, Neogenomics Inc (NASDAQ: NEO) closed at $12.12, up 0.41%. In other words, the price has increased by $0.41 from its previous closing price. On the day, 1.39 million shares were traded. NEO stock price reached its highest trading level at $12.25 during the session, while it also had its lowest trading level at $11.955.
Ratios:
Our goal is to gain a better understanding of NEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when Olivo Alicia C sold 20,916 shares for $12.00 per share. The transaction valued at 250,992 led to the insider holds 31,083 shares of the business.
ALICIA OLIVO bought 11,939 shares of NEO for $138,612 on Nov 25 ’25. On Oct 16 ’25, another insider, ALICIA OLIVO, who serves as the Officer of the company, bought 4,918 shares for $9.97 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1568180096 and an Enterprise Value of 1814371200. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.21 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 2.558 whereas that against EBITDA is -526.974.
Stock Price History:
The Beta on a monthly basis for NEO is 1.57, which has changed by -0.29784757 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $4.72. The 50-Day Moving Average of the stock is 20.72%, while the 200-Day Moving Average is calculated to be 42.09%.
Shares Statistics:
The stock has traded on average 3.35M shares per day over the past 3-months and 2147150 shares per day over the last 10 days, according to various share statistics. A total of 128.89M shares are outstanding, with a floating share count of 123.00M. Insiders hold about 4.94% of the company’s shares, while institutions hold 96.68% stake in the company. Shares short for NEO as of 1763078400 were 8416654 with a Short Ratio of 2.51, compared to 1760486400 on 6508598. Therefore, it implies a Short% of Shares Outstanding of 8416654 and a Short% of Float of 8.959999999999999.
Earnings Estimates
. The current rating of Neogenomics Inc (NEO) is the result of assessments by 12.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.01, with high estimates of $0.06 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.12 and $0.08 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.18, with 12.0 analysts recommending between $0.3 and $0.06.
Revenue Estimates
13 analysts predict $188.4M in revenue for. The current quarter. It ranges from a high estimate of $193M to a low estimate of $186.6M. As of. The current estimate, Neogenomics Inc’s year-ago sales were $172MFor the next quarter, 13 analysts are estimating revenue of $187.98M. There is a high estimate of $194.32M for the next quarter, whereas the lowest estimate is $183M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $730.2M, while the lowest revenue estimate was $723.7M, resulting in an average revenue estimate of $725.56M. In the same quarter a year ago, actual revenue was $660.57MBased on 13 analysts’ estimates, the company’s revenue will be $797.81M in the next fiscal year. The high estimate is $807.13M and the low estimate is $784.8M.
